Richard S Pottorf

US Patent:

20060014812, Jan 19, 2006

Filed:

Jul 8, 2005

Appl. No.:

11/177716

Inventors:

Mark Player - Phoenixville PA, US
Richard Pottorf - Belle Mead NJ, US
Dionisios Rentzeperis - Downingtown PA, US
Dibyendu De - Suwanee GA, US

International Classification:

A61K 31/426
A61K 31/42
A61K 31/415
A61K 31/198
A61K 31/277

US Classification:

514369000, 514378000, 514649000, 514621000, 514521000, 514567000, 514406000

Abstract:

Therapeutic methods of using certain heterocyclic arylidene aryl ether compounds for treating diseases or disorders mediated through modulation of estrogen related receptor alpha are described.

US Patent:

20100189644, Jul 29, 2010

Filed:

Jan 26, 2010

Appl. No.:

12/693863

Inventors:

DAVID W. CHRISTIANSON - Media PA, US
Bruce Edward Tomczuk - Collegeville PA, US
Richard Scott Pottorf - Belle Mead NJ, US
Andrew Vargha Colasanti - Scotch Plains NJ, US
Gary Lee Olson - Mountainside NJ, US

Assignee:

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - PHILADELPHIA PA
ARGINETIX, INC. - Lutherville MD

International Classification:

A61K 31/69
C07F 5/02
A61K 49/00
A61K 51/04
A61P 35/00
A61P 17/06
A61P 37/00
A61P 17/02
A61P 1/00

US Classification:

424 165, 562 7, 546 13, 544 69, 514 64, 424 91

Abstract:

The present invention is directed to arginase inhibitor compounds of formula IA or formula IB:or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

US Patent:

57863318, Jul 28, 1998

Filed:

Jun 5, 1995

Appl. No.:

8/465391

Inventors:

Ronald W. Barrett - Sunnyvale CA
Stephen D. Yanofsky - San Mateo CA
David Baldwin - Palo Alto CA
Jeff W. Jacobs - San Mateo CA
Phillipe R. Bovy - Los Altos CA
Ellen M. Leahy - San Leandro CA
Richard S. Pottorf - West Chester OH

Assignee:

Affymax Technologies N.V. - Greenford
Hoechst Marion Roussel, Inc. - Kansas City MO

International Classification:

A61K 3808
A61K 3800
C07K 704

US Classification:

514 15

Abstract:

Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amount of IL-1R, or an IL-1R agonist or antagonist, in a sample and comprise a sequence of amino acids selected from the group consisting of (1) WXXXGZ. sub. 1 W where Z. sub. 1 is L, I, A, or Q; (2) XXQZ. sub. 5 YZ. sub. 6 XX where Z. sub. 5 is P or Aze where Aze is azetidine; and Z. sub. 6 is S, A, V, or L; and (3) Z. sub. 23 NZ. sub. 24 SZ. sub. 25 Z. sub. 26 Z. sub. 27 Z. sub. 28 Z. sub. 29 Z. sub. 30 L where Z. sub. 23 is D or Y; Z. sub. 24 is D or S; Z. sub. 25 is S or W; Z. sub. 26 is S or Y; Z. sub. 27 is D or V; Z. sub. 28 is S or W; Z. sub. 29 is F or L; and Z. sub. 30 is D or L; and where each amino acid is indicated by standard one letter abbreviation; and each X can be selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids. Also provided are peptides which bind to the IL-1RtI, which are 11 to 40 amino acids in length, which comprise the core sequence of amino acids: Z. sub. 31 XWZ. sub. 32 Z. sub. 33 Z. sub. 34 Z. sub. 35 Z. sub. 36 QZ. sub. 37 Z. sub. 38 where each letter represents the standard one letter abbreviation for an amino acid or an analog thereof; X is selected from the group of natural or unnatural amino acids; Z. sub.

US Patent:

58614761, Jan 19, 1999

Filed:

Jun 5, 1995

Appl. No.:

8/464538

Inventors:

Ronald W. Barrett - Sunnyvale CA
Stephen D. Yanofsky - San Mateo CA
David Baldwin - Palo Alto CA
Jeff W. Jacobs - San Mateo CA
Phillipe R. Bovy - Los Altos CA
Ellen M. Leahy - San Leandro CA
Richard S. Pottorf - West Chester OH

Assignee:

Affymax Technologies N.V. - Greenford
Hoechst Marion Roussel, Inc. - Kansas City MO

International Classification:

C07K 704
A61K 3800
A61K 3804

US Classification:

530527

Abstract:

Peptides that bind to the interleukin-1 type I receptor (IL-1RtI) can be used to assay the amount of IL-1R, or an IL-1R agonist or antagonist, in a sample and comprise a sequence of amino acids selected from the group consisting of (1) WXXXGZ. sub. 1 W where Z. sub. 1 is L, I, A, or Q; (2) XXQZ. sub. 5 YZ. sub. 6 XX where Z. sub. 5 is P or Aze where Aze is azetidine; and Z. sub. 6 is S, A, V, or L; and (3) Z. sub. 23 NZ. sub. 24 SZ. sub. 25 Z. sub. 26 Z. sub. 27 Z. sub. 28 Z. sub. 29 Z. sub. 30 L where Z. sub. 23 is D or Y; Z. sub. 24 is D or S; Z. sub. 25 is S or W; Z. sub. 26 is S or Y; Z. sub. 27 is D or V; Z. sub. 28 is S or W; Z. sub. 29 is F or L; and Z. sub. 30 is D or L; and where each amino acid is indicated by standard one letter abbreviation; and each X can be selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids. Also provided are peptides which bind to the IL-1RtI, which are 11 to 40 amino acids in length, which comprise the core sequence of amino acids: Z. sub. 31 XWZ. sub. 32 Z. sub. 33 Z. sub. 34 Z. sub. 35 Z. sub. 36 QZ. sub. 37 Z. sub. 38 where each letter represents the standard one letter abbreviation for an amino acid or an analog thereof; X is selected from the group of natural or unnatural amino acids; Z. sub.

US Patent:

20200223871, Jul 16, 2020

Filed:

Aug 22, 2019

Appl. No.:

16/548681

Inventors:

- Sodertalje, SE
- Philadelphia PA, US
Richard Scott Pottorf - Belle Mead NJ, US
Andrew Vargha Colasanti - Scotch Plains NJ, US
Gary Lee Olson - Mountainside NJ, US

Assignee:

AstraZeneca AB - Sodertalje
The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

C07F 5/02
A61K 49/00

Abstract:

The present invention is directed to arginase inhibitor compounds of formula IA or formula IB:or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

US Patent:

20190194201, Jun 27, 2019

Filed:

Feb 27, 2019

Appl. No.:

16/287195

Inventors:

- Philadelphia PA, US
- Monmouth Junction NJ, US
Richard S. POTTORF - Indianapolis IN, US
Bhaskara Rao NALLAGANCHU - Hillsborough NJ, US
Gary OLSON - Mountainside NJ, US
Yanjun SUN - Kendall Park NJ, US

Assignee:

ONCOCEUTICS, INC. - Philadelphia PA

International Classification:

C07D 471/14
A61K 31/337
C07D 471/12
A61K 31/519
A61K 45/06
C07D 487/14

Abstract:

This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10):as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.

US Patent:

20190127395, May 2, 2019

Filed:

Sep 28, 2018

Appl. No.:

16/145559

Inventors:

- Sodertalje, SE
- Philadelphia PA, US
Richard Scott Pottorf - Belle Mead NJ, US
Andrew Vargha Colasanti - Scotch Plains NJ, US
Gary Lee Olson - Mountainside NJ, US

Assignee:

AstraZeneca AB - Sodertalje
The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

C07F 5/02
A61K 49/00

Abstract:

The present invention is directed to arginase inhibitor compounds of formula IA or formula IB:or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

US Patent:

20180072729, Mar 15, 2018

Filed:

Nov 20, 2017

Appl. No.:

15/817896

Inventors:

- Philadelphia PA, US
- Monmouth Junction NJ, US
Richard S. POTTORF - Indianapolis IN, US
Bhaskara Rao NALLAGANCHU - Hillsborough NJ, US
Gary OLSON - Mountainside NJ, US
Yanjun SUN - Kendall Park NJ, US

Assignee:

ONCOCEUTICS, INC. - Philadelphia PA

International Classification:

C07D 471/14

Abstract:

This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10):as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.